Evidence map›Paper›PMID 25626682›Full record

ArticleThe Journal of general virology2015

Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation.

Mohamed El-Far, Petronela Ancuta, Jean-Pierre Routy, Yuwei Zhang, Wendy Bakeman, Rebeka Bordi, Sandrina DaFonseca, Elias A Said, Annie Gosselin, Tévy-Suzy Tep and 7 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of general virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Immune checkpoint blockade in infectious diseases.Nature reviews. Immunology · 2018
    Review
  12. Article
  13. CTLA-4Immunity · 2017
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Mohamed El-FarDepartment of Microbiology, Infectiology and Immunology, Université de Montréal, Québec, Canada.
Petronela AncutaDepartment of Microbiology, Infectiology and Immunology, Université de Montréal, Québec, Canada.
Jean-Pierre RoutyDivision of Hematology and Chronic Viral Illness Service, McGill University Health Centre, McGill University, Montréal, Québec, Canada.
Yuwei ZhangVaccine & Gene Therapy Institute Florida, Port St Lucie, FL, USA.
Wendy BakemanVaccine & Gene Therapy Institute Florida, Port St Lucie, FL, USA.
Rebeka BordiVaccine & Gene Therapy Institute Florida, Port St Lucie, FL, USA.
Sandrina DaFonsecaVaccine & Gene Therapy Institute Florida, Port St Lucie, FL, USA.
Elias A SaidDepartment of Microbiology, Infectiology and Immunology, Université de Montréal, Québec, Canada.
Annie GosselinCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Tévy-Suzy TepDepartment of Microbiology, Infectiology and Immunology, Université de Montréal, Québec, Canada.
Quentin EichbaumVanderbilt University, School of Medicine, Nashville, TN, USA.
Julien van GrevenyngheVaccine & Gene Therapy Institute Florida, Port St Lucie, FL, USA.
Olivier SchwartzVirus and Immunity Group, Department of Virology, Institut Pasteur, Paris, France.
Gordon J FreemanDana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Elias K HaddadVaccine & Gene Therapy Institute Florida, Port St Lucie, FL, USA.
Nicolas ChomontVaccine & Gene Therapy Institute Florida, Port St Lucie, FL, USA.
Rafick-Pierre SékalyCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Centre Hospitalier de l’Université de Montréal · CAUniversité de Montréal · CAVaccine and Gene Therapy InstituteVaccine & Gene Therapy Institute of Florida · USHarvard University · USInstitut Pasteur · FRMcGill University Health Centre · CAVanderbilt University · US

Funding

Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5M
Canadian Institutes of Health Research 103230Canadian Institutes of Health Research CTN 257NIAID NIH HHS U19 AI096109NIAID NIH HHS U19 AI096109-03PHS HHS IDPIDA028871-01
6 · The paper itself

Abstract

CTLA-4 is a negative regulator of T-cell receptor-mediated CD4(+) T-cell activation and function. Upregulation of CTLA-4 during human immunodeficiency virus type 1 (HIV-1) infection on activated T cells, particularly on HIV-specific CD4(+) T cells, correlates with immune dysfunction and disease progression. As HIV-1 infects and replicates in activated CD4(+) T cells, we investigated mechanisms by which HIV-1 modulates CTLA-4 expression to establish productive viral infection in these cells. Here, we demonstrate that HIV-1 infection in activated CD4(+) T cells was followed by Nef-mediated downregulation of CTLA-4. This was associated with a decreased T-cell activation threshold and significant resistance to CTLA-4 triggering. In line with these in vitro results, quantification of pro-viral HIV DNA from treatment-naive HIV-infected subjects demonstrated a preferential infection of memory CD4(+)CTLA-4(+) T cells, thus identifying CTLA-4 as a biomarker for HIV-infected cells in vivo. As transcriptionally active HIV-1 and Nef expression in vivo were previously shown to take place mainly in the CD3(+)CD4(-)CD8(-) [double-negative (DN)] cells, we further quantified HIV DNA in the CTLA-4(+) and CTLA-4(-) subpopulations of these cells. Our results showed that DN T cells lacking CTLA-4 expression were enriched in HIV DNA compared with DN CTLA-4(+) cells. Together, these results suggested that HIV-1 preferential infection of CD4(+)CTLA-4(+) T cells in vivo was followed by Nef-mediated concomitant downregulation of both CD4 and CTLA-4 upon transition to productive infection. This also highlights the propensity of HIV-1 to evade restriction of the key negative immune regulator CTLA-4 on cell activation and viral replication, and therefore contributes to the overall HIV-1 pathogenesis.

Indexed as

Host-Pathogen InteractionsImmune EvasionAdultCD4-Positive T-LymphocytesCTLA-4 AntigenFemaleGene Expression RegulationHIV-1HumansMalenef Gene Products, Human Immunodeficiency VirusT-Lymphocytes, CytotoxicCTLA-4 Antigennef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1

Identifiers

PMID25626682
PMCPMC4635491
OpenAlexW1808380378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.